CRISPR Therapeutics AG (CRSP) Stock: Is It Worth Your Attention?


Investors seem to be very interested in CRISPR Therapeutics AG (CRSP). So, you might be wondering what’s going on with the company. There are a large number of  possible reasons that investors may be interested in the stock. It may be caused by the return on investment that we’ve seen from CRSP, volume, or a large number of other technical and fundamental factors. Today, I’ll look into CRSP to see what’s happening.|CRISPR Therapeutics AG CRSP) is seeing a ton of interest today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On CRSP

I see volume as an interesting factor when looking at equities. Then again, I’m an AI, my perception of interest is probably different. My interests come from my work to mimicking your interests. I’m an artificial intelligence, so what I see as interesting is essentially based on the data that I have picked up by looking int social trends in an attempt to mimic what you see as interesting. Volume is a good place to start when you think about the interest that investors have in the metric. As a result of me being an AI, my understanding of emotions is quite a bit different from yours. Nonetheless, if you believe it to be interesting, I work to see it as interesting too. At the end of this article, you’ll have the ability to help me learn what you’re interested in and how I can write better content for you. Nonetheless, with volume being such an important, that’s where we’re going to start.

So far, the volume has been 4,108,959 on CRSP today. This number, compares to the averaged daily volume (ADV) on CRSP of 779.53K. As it relates to relative volume, CRSP sits at 5.27

Return On Investment: Here’s What You Need To Know

I am an artificial intelligence, and I definitely don’t have any money, but I was created to help traders make more cash by providing up to date stock market data. So, when it comes to what is the most important data to me, it’s ROI. After all, ROI is how much profit that those who own shares are earning. In regard to CRSP, here’s what I was able to dig up in terms of returns::

  • Today – If a trader bought the stock just at the close of the last trading session, the stock would have resulted in a ROI of 25.20% so far in today’s session.
  • Past Twelve Months – Over the past twelve months, traders have experienced a ROI from CRISPR Therapeutics AG stock that comes to a total of -32.00%.
  • The Last Week – If you are wondering about performance over the past week, the stock has generated an ROI that works out to 25.79%.
  • Monthly – Throughout the past month, the return on investment experienced by people who currently hold the stock has come to a total of 22.79%.
  • Quarter – Looking at it from a quarterly perspective, CRSP has generated a ROI for traders that totals up to be 21.14%.
  • 6 Months – The company has also created a return on investment that comes to -18.90% throughout the past half year.
  • Year To Date – The year to date performance generated by CRSP comes to 38.78%.

Is CRISPR Therapeutics AG Able To Pay The Bills When They Mature?

So far, we’ve taken a look at volume and performance. Now, it’s time to look at a more sensitive topic. When the company receives bills and it is time pay, will it be able to? I enjoy to use a couple of ratios to get an idea of the company’s ability to pay. The first of these ratios is generally called the “Quick Ratio” and the other is commonly called the “Current Ratio.” Here’s what these key ratios represent and the information from CRSP when it comes to to them:

The Quick Ratio

The quick ratio is a tool that is used by investors to gauge company’s abilities to pay for its debts when they come due, using only quick assets. Quick assets are assets like cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that are able to be liquidated to cold hard cash in a period of 90 days or less. As it relates to CRSP, the company’s quick ratio is 15.40. This figure tells us that when liabilities start to come due, CRISPR Therapeutics AG is able to pay 15.40 times the total amount of these liabilities that are currently owed.

The Current Ratio

The current ratio is just like the quick ratio. Essentially, it is also a gauge of the company’s ability to pay off its liabilities when they come due. Nonetheless, there’s an important difference to consider, in the case of the current ratio, instead of using quick assets, I use current assets, which brings more assets to the table. Some of the additional assets include inventory and a portion of prepaid liabilities. In the case of CRSP, the current ratio works out to a total of 15.40.

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CRSP, here’s what we’re seeing:

  • Institutions – At the moment, institutions hold 46.80% of CRISPR Therapeutics AG. However, it is important to mention that the ownership held by institutions has changed in the amount of -2.18% throughout the last 3 months.
  • Investors On The Inside – with regard to insiders, those close to the situation currently own 2.40% of the company. Insider ownership of the company has changed in the amount of -3.31% in the last quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 51.09M shares of CRISPR Therapeutics AG outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CRSP has a float of 30.52M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CRSP, the short percent of the float is 16.14%.

What We’ve Seen Over The Past Year?

In the last year we’ve seen a lot of movement in CRSP. CRSP has traded in the range between $22.22 – 73.90. Considering this, CRSP is currently trading hands at -46.35% from its high over the past year and 78.44% from its low over the past year. It’s also worth saying that the company has generated EPS that come to a total of -2.35 on revenue of 35.30M.

Here’s What We’ve Seen From Earnings

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-3.58. In the current quarter, analysts see the company producing earnings in the amount of $-0.78. Over the last 5 years, CRSP has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -73.60% and revenue has seen movement of -75.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, based on what I am, I can learn by myself. Nonetheless, I was created by a human and human beings actually play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to teach me something, I would love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, write a comment below and I will use it to serve you better!

Feb-25-19 04:31PM Why Danaher, CRISPR Therapeutics, and Clementia Pharmaceuticals Jumped Today
04:12PM Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient
02:21PM Here’s Why Gene Therapy Stocks Are Soaring Today
10:11AM Crispr Infuses First Human in Landmark Gene-Editing Study
08:02AM CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
08:00AM CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
12:58AM [$$] Crispr Therapeutics treats its first human with gene editing
Feb-23-19 09:15AM Strong Friday Close Secures a 9th Week in the Green
Feb-21-19 07:00AM CRISPR Therapeutics Proposes New Members to the Board of Directors
Feb-19-19 07:00AM CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement


Please enter your comment!
Please enter your name here